NAUT PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

NAUT ▼ -6.18% at T+20d

NEUTRAL call ✗ call lost -6.18% · α vs SPY -11.65% · entry $2.59 → $2.43

Next anchor: T+60d in 6w

Currently $2.35 · -9.27% from $2.59 entry

Entry anchored
Apr 27, 03:59 PM ET
via Databento tick

T+1d

-3.47%

call -3.47% · α -3.47%

$2.50

settled 6w ago

T+5d

+11.58%

call +11.58% · α +9.89%

$2.89

settled 5w ago

T+20d

-6.18%

call -6.18% · α -11.65%

$2.43

settled 14d ago

T+60d

—

call — · α —

—

in 6w

Price Chart

Loading chart...

Executive Summary

Nautilus Biotechnology reported Q1 2026 EPS of -$0.12, beating consensus of -$0.14 by 17.2%, with revenue still at $0 as a pre-commercialization stage company. Operating expenses fell 14% YoY to $16.1M, and net loss narrowed to $14.7M from $16.6M, while cash and investments stood at $143.4M. The beat is modest for a development-stage firm with no revenue, but the narrowing loss and cash runway extension are incremental positives.

Key Financial Metrics

Free Cash Flow

-$13.6M

Actionable Insight

The EPS beat and narrowing loss are incremental positives, but with zero revenue and no guidance provided, the stock remains a binary event on commercial launch timing. Monitor for Early Access customer expansions and next-gen assay development milestones as catalysts.

Key Facts

Q1 2026 EPS: -$0.12 vs consensus -$0.14 (17.2% beat)
Revenue: $0 (pre-commercialization, no consensus revenue estimate)
Operating expenses: $16.1M, down 14% YoY from $18.8M
Net loss: $14.7M vs $16.6M YoY, narrowing by 11.5%
Cash, cash equivalents, and investments: $143.4M as of March 31, 2026
Initiated Iterative Mapping Early Access Program with Baylor College of Medicine
Appointed Amber Faust as VP of Global Sales from Olink/SomaLogic

Financial Impact

EPS beat of $0.02 vs consensus, net loss improved by $1.9M YoY

epsnet lossoperating expensescash runway

Risk Factors

No revenue and pre-commercialization stage — binary outcome on platform launch success
Cash burn of ~$13.1M operating cash flow per quarter implies ~11 quarters of runway
No guidance provided, limiting forward visibility

Market Snapshot

Exchange

Nasdaq

Sector

Laboratory Analytical Instruments

Analyst Consensus

88% bullish (8 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3282599

4 reports for NAUT

T+1T+5T+20T+60

Filters

Reports for NAUT — sortable, filterable
	Type				Now
Apr 28, 2026 6w ago	Press Release NEUTRAL ★ 4/10	$2.59 $2.43	▼ −6.18%	▼ −11.65%	$2.35 (−9.27%)
Apr 28, 2026 6w ago	8-K NEUTRAL ★ 4/10	$2.59 $2.56	▼ −1.16%	▼ −6.61%	$2.35 (−9.27%)
Mar 18, 2026 11w ago	Press Release MIXED ★ 6/10	$2.74 $3.13	▲ +14.05%	▲ +8.00%	$2.35 (−14.23%)
Feb 26, 2026 14w ago	8-K NEUTRAL ★ 4/10	$2.42 $3.78	▲ +56.20%	▲ +62.60%	$2.35 (−2.89%)

US Market Status

Market Closed — Opens Thu (10h 5m)

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access